Updates and Perspectives on Third-Generation EFGR TKIs in Advanced NSCLC.

Slides:

Advertisements

Similar presentations

Activity and Tolerability of Afatinib (BIBW 2992) and Cetuximab in NSCLC Patients with Acquired Resistance to Erlotinib or Gefitinib Janjigian YY et al.

Advertisements

Nuovi inibitori irreversibili di EGFR

May 29 - June 2, 2015 TIGER-X: Rociletinib Activity in EGFR T790M Mutant NSCLC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting* *CCO.

J Thorac Oncol. 2012;7: 1653–1660) David P. Carbone, MD, PhD,* Keyue Ding, PhD,† Heinrich Roder, PhD,‡ Julia Grigorieva, PhD,‡ Joanna Roder, PhD,‡ Ming-Sound.

Anna Buder Institute of Cancer Research Department of Medicine I Medical University of Vienna Liquid Biopsies Analysis of circulating cell-free tumor-DNA.

BLOOM: Osimertinib Shows Promising Activity in Patients With EGFRm+ Advanced NSCLC and Leptomeningeal Metastases CCO Independent Conference Coverage* of.

Rosell R et al. Proc ASCO 2011;Abstract 7503.

Endocrine Combinations in HR-Positive MBC: The Future Is Now

Patient Case 1 Patient Case 1: PET/CT Scan.

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

Crystal digital PCR for detection and quantification of circulating EGFR mutations in advanced non-small cell lung cancer Cécile Jovelet Postdocoral fellow.

Strategies for the Management of EGFR TKI Resistance in Advanced NSCLC

Pharmacy Perspectives in Multiple Myeloma: Relapsed and/or Refractory Disease.

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

The New Taxonomy of Metastatic NSCLC and Physician Treatment Based on Pathologic and Molecular Characteristics The New Taxonomy of Metastatic Non-Small.

Fundamental Concepts in the Diagnosis of Advanced NSCLC

Assessing the Impact: New Data in T790+ NSCLC

New Patient Journeys in Non-small cell lung cancer

Progression After Cancer Immunotherapy in Advanced NSCLC

The Genomics of Cancer and Molecular Testing:

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

Updates in Lung Cancer: Insights From Vienna

Proof-of-concept clinical studies validating AZD9291 as a mutant-selective EGFR kinase T790M inhibitor. Proof-of-concept clinical studies validating AZD9291.

Optimizing Outcomes in the Management of GIST

Supplemental Figure 1 A B Alteration Time 1 (AF) Time 2 (AF)

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference

Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic.

EGFR Inhibitors in Advanced NSCLC: Who, When, and Why?

More Than Meets the Eye.

Treatment of HR+ Breast Cancer: A Clinical Update

Moving Care Forward in Advanced NSCLC

EGFR-Mutated NSCLC and CNS Involvement: the Conundrum

Managing Polycythemia Vera in the Community Setting

Noemi Reguart Hospital Clínic de Barcelona

University of British Columbia British Columbia Cancer Agency

Putting Evidence Into Practice: Highlights From Toronto

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

Practical Guidance on the Management of Pan-Negative NSCLC

Practical Strategies to Guideline-Recommended Biomarker Testing in NSCLC.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Multidisciplinary Management in Non-Small Cell Lung Cancer (NSCLC)

Optimizing Characterization of NSCLC Through Specialty Collaboration

THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

Jamie A. Saxon, PhD, Lynette M. Sholl, MD, Pasi A. Jänne, MD, PhD

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

Educational Objectives

This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.

XL647—A Multitargeted Tyrosine Kinase Inhibitor: Results of a Phase II Study in Subjects with Non-small Cell Lung Cancer Who Have Progressed after Responding.

AMD Therapy: Where Are We Now and Where Are We Going?

Checkpoint Inhibitors in First-Line Advanced NSCLC

Third-Generation EGFR TKIs

Compound Uncommon EGFR Mutations in a Patient with Advanced NSCLC and Durable Response to Sequential EGFR Targeted Therapies Mary Linton B Peters, MD,

The Nurse View: Spotlight on EGFR-Mutated NSCLC

Finding the Right Sequence in Patients With EGFR-Mutated NSCLC

Physiologic vs Chronologic Age

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

What's on the Horizon in the Management of EGFR-Mutated Lung Cancer?

Detection of somatic mutations in plasma allows for non-invasive real time therapy response monitoring of lung cancer patients José Carlos Machado.

Combining Immunotherapy and Chemotherapy in NSCLC

Physiologic vs Chronologic Age

Location of common clinically relevant mutations in EGFR

Updates in Best Practices in Non-Small Cell Lung Cancer

Response and resistance to savolitinib and osimertinib in a patient with EGFR-mutant NSCLC harboring MET amplification. Response and resistance to savolitinib.

Presentation transcript:

Updates and Perspectives on Third-Generation EFGR TKIs in Advanced NSCLC

Third-Generation EFGR TKIs in Advanced NSCLC

Osimertinib

AURA Study: Phase 2 Expansion Cohort in First Line Patients Results

Osimertinib – Adverse Events

FLAURA Trial: Osimertinib vs Gefitinib or Erlotinib in Treatment-Naive Patients

EGFR C797S -- Resistance to Osimertinib

BLOOM Phase 1 Trial: Osimertinib Activity in Leptomeningeal Disease From NSCLC

BLOOM Phase 1 Trial -- Results

Olmutinib (BI 1482694) in Patients With T790M+ Advanced NSCLC

Olmutinib (BI 1482694) -- Results

Rociletinib for EGFR T790M+ NSCLC

ASP8273 (300 mg) in EGFR+ NSCLC: Interim Results

EGFR Exon 20 Insertions in NSCLC

EGF816: in EGFR Advanced NSCLC T790M+ Patients

Patients Who Have Progressed on Third-Generation EGFR TKIs

Ongoing Trials

Biomarker Testing in Advanced NSCLC

Applications of Liquid Biopsy

Limitations to Plasma-Based Testing

Conclusions

Abbreviations

Abbreviations (cont)